AGP Executive Report
Last update: 8 hours agoSwiss Markets: The SMI ended up 0.34% at 14,334.79, helped by stronger July retail sales despite worries over rates and global growth. UBS Capital Fight: Swiss lawmakers backed a softer approach to UBS capital rules, a move that keeps the bank’s regulatory battle in focus. Pharma Watch: Novartis paused eight autoimmune drug trials after three deaths tied to a severe immune reaction, while a separate Phase 3 readout for an MS pill (remibrutinib) boosted confidence. Corporate Moves (Switzerland): Sudarshan agreed to buy Clariant’s aluminium dyes plant in Muttenz, taking control of a key supply site ahead of a 2027 close. Tech & Security: xorlab secured €5m to scale sovereign email security across Europe, and Swiss banking/ID-related policy debates continue as governments push for tighter controls. Global Risk Mood: Europe’s stocks slipped as bond yields rose and geopolitical tensions weighed sentiment.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
